Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Breast Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Eugene

EMBER-3: A Phase 3, Randomized, Open-Label, Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

  • Details

ClinicalTrials.gov ID: NCT04975308
Diagnosis Type: Breast Cancer
USOR Number: 21183

  • Practice Details

520 Country Club Rd
Eugene, OR 97401
P: (541) 683-5001

More Details View Practice Page

Breast Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Corvallis

EMBER-3: A Phase 3, Randomized, Open-Label, Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

  • Details

ClinicalTrials.gov ID: NCT04975308
Diagnosis Type: Breast Cancer
USOR Number: 21183

  • Practice Details

444 NW Elks Drive
Corvallis, OR 97330
P: (541) 754-1256

More Details View Practice Page

Leukemia

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Eugene

A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12301)

  • Details

ClinicalTrials.gov ID: NCT04971226
Diagnosis Type: Leukemia
USOR Number: 21171

  • Practice Details

520 Country Club Rd
Eugene, OR 97401
P: (541) 683-5001

More Details View Practice Page

Lung Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Eugene

A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

  • Details

ClinicalTrials.gov ID: NCT04622007
Diagnosis Type: Lung Cancer
USOR Number: 20423

  • Practice Details

520 Country Club Rd
Eugene, OR 97401
P: (541) 683-5001

More Details View Practice Page

Lung Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Eugene

A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

  • Details

ClinicalTrials.gov ID: NCT04819100
Diagnosis Type: Lung Cancer
USOR Number: 20412

  • Practice Details

520 Country Club Rd
Eugene, OR 97401
P: (541) 683-5001

More Details View Practice Page

Breast Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Eugene

A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE, HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

  • Details

ClinicalTrials.gov ID: NCT04961996
Diagnosis Type: Breast Cancer
USOR Number: 20408

  • Practice Details

520 Country Club Rd
Eugene, OR 97401
P: (541) 683-5001

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Eugene

A PHASE 2, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN’S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

  • Details

ClinicalTrials.gov ID: NCT04562870
Diagnosis Type: Myelofibrosis
USOR Number: 20346

  • Practice Details

520 Country Club Rd
Eugene, OR 97401
P: (541) 683-5001

More Details View Practice Page

Lymphomas

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Eugene

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

  • Details

ClinicalTrials.gov ID: NCT04666038
Diagnosis Type: Lymphomas
USOR Number: 20343

  • Practice Details

520 Country Club Rd
Eugene, OR 97401
P: (541) 683-5001

More Details View Practice Page

Lymphomas

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Eugene

A Phase 3, Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

  • Details

ClinicalTrials.gov ID: NCT04662255
Diagnosis Type: Lymphomas
USOR Number: 20336

  • Practice Details

520 Country Club Rd
Eugene, OR 97401
P: (541) 683-5001

More Details View Practice Page

Lung Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Eugene

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202)

  • Details

ClinicalTrials.gov ID: NCT04620330
Diagnosis Type: Lung Cancer
USOR Number: 20331

  • Practice Details

520 Country Club Rd
Eugene, OR 97401
P: (541) 683-5001

More Details View Practice Page